Jiangsu Lianhuan Pharmaceutical Balance Sheet Health
Financial Health criteria checks 4/6
Jiangsu Lianhuan Pharmaceutical has a total shareholder equity of CN¥1.6B and total debt of CN¥816.5M, which brings its debt-to-equity ratio to 51.7%. Its total assets and total liabilities are CN¥3.0B and CN¥1.5B respectively. Jiangsu Lianhuan Pharmaceutical's EBIT is CN¥189.5M making its interest coverage ratio 6.9. It has cash and short-term investments of CN¥207.2M.
Key information
51.7%
Debt to equity ratio
CN¥816.50m
Debt
| Interest coverage ratio | 6.9x |
| Cash | CN¥207.18m |
| Equity | CN¥1.58b |
| Total liabilities | CN¥1.45b |
| Total assets | CN¥3.03b |
Recent financial health updates
No updates
Recent updates
Improved Earnings Required Before Jiangsu Lianhuan Pharmaceutical Co., Ltd. (SHSE:600513) Stock's 25% Jump Looks Justified
Nov 08
Jiangsu Lianhuan Pharmaceutical's (SHSE:600513) Profits Appear To Have Quality Issues
Sep 11We Think That There Are More Issues For Jiangsu Lianhuan Pharmaceutical (SHSE:600513) Than Just Sluggish Earnings
Mar 12Financial Position Analysis
Short Term Liabilities: 600513's short term assets (CN¥1.4B) do not cover its short term liabilities (CN¥1.4B).
Long Term Liabilities: 600513's short term assets (CN¥1.4B) exceed its long term liabilities (CN¥21.3M).
Debt to Equity History and Analysis
Debt Level: 600513's net debt to equity ratio (38.6%) is considered satisfactory.
Reducing Debt: 600513's debt to equity ratio has increased from 19.9% to 51.7% over the past 5 years.
Debt Coverage: 600513's debt is well covered by operating cash flow (23.9%).
Interest Coverage: 600513's interest payments on its debt are well covered by EBIT (6.9x coverage).